Cipla Ltd
NSE: CIPLA BSE: 500087
₹1314.50
(-1.08)%
Mon, 02 Feb 2026, 03:53 am
Market Cap1069.45B
PE Ratio23.36
Dividend0.98
Health Technology
Pharmaceuticals: Other
24.5KAnalysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (6.4x coverage).
- Dividends after 3 years are expected to be well covered by earnings (6.2x coverage).
- Dividends per share have been stable in the past 10 years.
- Cipla's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Cipla's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cipla's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Cipla's earnings are expected to exceed the low risk growth rate next year.
- Cipla's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- An improvement in Cipla's performance (ROE) is expected over the next 3 years.
- Cipla's revenue growth is expected to exceed the India market average.
- Cash flow for Cipla is expected to decrease over the next 2 years.
- Cipla's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
- Cipla's earnings growth is positive but not above the India market average.
- Cipla's net income is expected to increase but not above the 50% threshold in 2 years time.
- Cipla is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- Cipla's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Cipla's revenue is expected to grow by 7.9% yearly, however this is not considered high growth (20% yearly).
health
- Cipla is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Cipla is profitable, therefore cash runway is not a concern.
- Cipla is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (108.9%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 4.2x debt.
- Cipla's cash and other short term assets cover its long term commitments.
- Cipla earns more interest than it pays, coverage of interest payments is not a concern.
- Cipla's level of debt (17.5%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (16% vs 17.5% today).
- High level of physical assets or inventory.
management
- The tenure for the Cipla board of directors is about average.
- Umang's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Cipla management team is about average.
- Umang's remuneration is higher than average for companies of similar size in India.
- Cipla individual insiders have only sold shares in the past 3 months.
misc
- Cipla has significant price volatility in the past 3 months.
past
- Cipla's year on year earnings growth rate has been positive over the past 5 years.
- Cipla has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Cipla's 1-year earnings growth is less than its 5-year average (1.2% vs 3.4%)
- Cipla used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Cipla has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Cipla's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (1.2% vs 22.7%).
value
- CIPLA outperformed the Market in India which returned -14.5% over the past year.
- NSEI:CIPLA is up 11.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:CIPLA is up 11.8% outperforming the market in India which returned 8% over the past month.
- Cipla's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Cipla's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Cipla is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Cipla is poor value based on expected growth next year.
- Cipla is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Cipla is overvalued based on earnings compared to the India market.
- CIPLA underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800